The Effect Of Pet Therapy Applıed To Elders's Sleep And Qualıty Of Lıfe

The Effect Of Pet Therapy Applıed To Elderly Indıvıduals Lıvıng In A Nursıng Home On Sleep And Qualıty Of Lıfe

Quality of life is defined as functional abilities that include the ability to fulfill an individual social role, the degree and quality of social interaction, mental health, physical competence, somatic senses such as pain, and satisfaction with life. The World Health Organization (WHO) defined quality of life in 1947 as a decrease not only in disease, disorder or disability, but also in physical, mental and social well-being. Old age is one of the situations in which the quality of life decreases. It is reported that the poor social and financial situation of individuals, low educational level, gender, lack of physical movement, decreased daily life activity level, decreased mobility ability, fall anxiety, sleep problems and other conditions that cause disability are determinants of the quality of life. According to the results of Bloom et al.'s study, elderly people wake up at night due to health problems.

According to the literature, the sleep and life of pet therapy applied to elderly individuals living in a nursing home there have not been any studies examining the effect on quality. For this reason, it was aimed to conduct this study in order to determine the effect of pet therapy applied to elderly individuals living in a nursing home on sleep and quality of life.

The study was planned to be conducted in a randomized controlled manner in order to determine the effect of pet therapy applied for one hour twice a week for 6 weeks to elderly people living in a nursing home in Tokat province on sleep pattern and quality of life. In the study, gender, age group and the presence of chronic diseases were taken as equivalence criteria. Since conducting the study single-blind will increase the reliability of the study, the application of the scales was applied by another researcher/surveyor other than the main researcher.

Study Overview

• Status: Completed
• Conditions: Pet Therapy Effect of Sleep and Quality of Life
• Intervention / Treatment: Other: Pet Therapy

Detailed Description

The study was planned to be conducted in a randomized controlled manner in order to determine the effect of pet therapy applied for one hour twice a week for 6 weeks to elderly people living in a nursing home in Tokat province on sleep pattern and quality of life.

The universe of the research consists of 74 elderly elderly individuals who are located in a nursing home in Tokat province and meet the criteria for inclusion.

As a result of the calculations; the minimum sample volume that will provide the test power (1-β) = 0.95 was calculated as a total of 46 (23 interventions + 23 controls) people, and the net power of this study was determined as 0.952.

In the research, the data will be collected through the 'Elderly Person Introduction Form" CASP-19 Quality of Life Scale and PUKI sleep quality scale and Mini Mental Test (MMT). Since conducting the study double-blind will increase the reliability of the study, the application of the scales was applied by another researcher/surveyor other than the main researcher.

The Control Group Protocol:

The elderly in this group have not been given any treatment, they have received routine nursing home care and necessary treatments if any. The first evaluation of the elderly in the control group, 6.week and 10.the necessary measurements were made with the scales three times a week in total. The scales were collected by the questionnaire by face-to-face interview method.

Intervention Group Protocol:

After the data collection process of the control group was completed, the data collection process of the intervention group and pet therapy were applied. As a result of literature review; there is no clear duration for pet therapy and it was found that the average activity duration was 10-30 minutes, 4-12 weeks and 6-24 sessions. Based on this literature information; for this research, pet therapy pet therapy was applied for a total of 6 weeks and 12 sessions, 2 times a week for an average of 20 minutes for each elderly individual. End of therapy 6.week rating and 10.the scale was applied three times in total, including control measurement after a week of therapy. The scales applied by the animal therapy researcher were collected by the face-to-face interview method by the interviewer who did not know the groups.

In the evaluation of data, IBM SPSS Statistics 25.0 (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0.Armonk, NY: IBM Corp.) the statistical package program was used. The normal distribution of the data of numerical variables was evaluated by Shapiro-Wilk normality test/Kruskal Wallis test and Q-Q graphs. Spearman correlation analysis was performed to determine the relationship between the dimensions. Dec. Statistically, a value of p≤0.05 was considered significant.

• Study Type: Interventional
• Enrollment (Actual): 59
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Center
    • Tokat, Center, Turkey, 60000
      • Nursing home

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Tokat- Living in a nursing home,
• According to expert opinion, elderly people who received a minimum of 24 points in Mini Mental Test assessments,
• Able to communicate,
• Those who are not immobile and able to do activities with a dog,
• Not allergic to a dog,
• Not having a phobia of dogs,
• Sedative / antisedative, insomnia / hypersomnia,
• Elderly who agreed to participate in the study

Exclusion Criteria:

• People who are immobile and unable to do activities with the dog,
• Individuals who cannot communicate,
• (According to expert view)Those who score below 24 points of Mini Mental Test,
• Those who are allergic to dogs,
• Those who have a phobia of dogs,
• Those who use medications that will affect sleep processes, such as sedatives /antisedatives, insomnia/hypersomnia,
• People who do not want to participate in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention Group; Pet therapy was applied to the individuals in the intervention group for 6 weeks in addition to their normal routine lives. This therapy was applied every 20 minutes, 2 days a week. Repeated measurements were made before therapy, at the end of therapy and 4 weeks after the end of therapy. The scales were collected by the questionnaire by face-to-face interview method.	Other: Pet Therapy; Pet therapy was applied to the individuals in the intervention group for 6 weeks in addition to their normal routine lives. This therapy was applied every 20 minutes, 2 days a week. Repeated measurements were made before therapy, at the end of therapy and 4 weeks after the end of therapy.
No Intervention: Control Group; The elderly in this group have not been given any treatment, they have received routine nursing home care and necessary treatments if any. The first evaluation of the elderly in the control group, 6.week and 10.the necessary measurements were made with the scales three times a week in total. The scales were collected by the questionnaire by face-to-face interview method.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
PUKI	PUKI was developed by Buysse et al. in 1989 and has been shown to have sufficient internal consistency (Cronbach alpha= 0.80), test-retest reliability and validity (Buysse Reynolds Monk Berman and Kupfer 1989). The validity and reliability study of PUKI in our country was conducted by Ağargün et al. In this study, the Cronbach alpha value of the scale was found to be 0.79 (Cronbach alpha= 0.79). The total score has a value between 0-21.Dec. High values indicate that the quality of sleep is poor, the level of sleep disorders is high. A total score above 5 indicates that sleep quality is clinically poor.	First week, the end of six week and end of ten week.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CASP-19 QUALITY OF LIFE	The CASP-19 scale was developed by Hyde et al. in 2003 to measure the quality of life of elderly people. The scale consists of 19 items. The items of the scale are scored between 0-3 points.Dec. An increase in the total score indicates an increase in the quality of life. As a result of the factor analysis conducted by Hyde et al. for structure validity, it was found that the scale consists of 4 sub-dimensions, the Cronbach's alpha values of each sub-dimension are between 0. Dec.9-Dec.77, the item total score correlation coefficients are between r= 0.35 and r= 0.67.	First week, the end of six week and end of ten week.

Collaborators and Investigators

• Sponsor: Tokat Gaziosmanpasa University
• Investigators: Principal Investigator: Cansu YILMAZ, https://www.gop.edu.tr/AkademikOzgecmis/6508/cansu-yilmaz; Study Director: Pınar TEKINSOY KARTIN, https://avesis.erciyes.edu.tr/ptekinsoy

Study record dates

Study Major Dates

• Study Start (Actual): November 15, 2021
• Primary Completion (Actual): May 12, 2022
• Study Completion (Actual): June 22, 2023

Study Registration Dates

• First Submitted: February 27, 2024
• First Submitted That Met QC Criteria: February 27, 2024
• First Posted (Actual): March 5, 2024

Study Record Updates

• Last Update Posted (Actual): March 15, 2024
• Last Update Submitted That Met QC Criteria: March 13, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: sleeplessness; pet therapy; poor quality of life; problems of sleeping; nursing practices
• Other Study ID Numbers: AIBU-SBF-CY-09

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No